Compare TG Therapeutics Inc (TGTX) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs VF Corp — how do they compare? TG Therapeutics Inc trades at $49.58 (market cap $7.64B), while VF Corp trades at $14.7 (market cap $5.81B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and VF Corp pays a 2.44% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VFC | |
|---|---|---|
Market Cap | $7.64B | $5.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $21.55 |
52-Week Low | $26.94 | $12.21 |
Enterprise Value | $7.84B | $10.09B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
VFC trades at $14.70, down 1.34% over 24 hours, with a bearish technical signal and neutral oscillators. Recent earnings showed a Q2 2026 miss with a loss of $0.27 per share versus a $0.22 loss expected, though Q4 2025 beat expectations. Revenue declined to $9.50 billion in 2025, with a net loss of $189.72 million, while the company maintains a gross margin of 54.97%. Deleveraging progress continues, but Vans brand performance remains a headwind.
The outlook is mixed; analyst consensus is a 'Hold' with a $17.44 price target, implying potential upside. Risks include persistent Vans weakness, macroeconomic pressures, and competitive dynamics. Positive catalysts include raised fiscal 2027 revenue guidance and margin improvements, but execution on brand turnaround is critical for stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
